Clinical Trial

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study used a randomized, controlled, double-blind, multicenter Phase III clinical design with overall survival (OS) as the primary endpoint. About 165 patients with advanced biliary carcinoma were enrolled and randomly assigned to the experimental group and the control group in a 2:1 ratio to receive TQB3454 tablets or the placebo, respectively, to evaluate the efficacy and safety of TQB3454 tablets in the treatment of advanced biliary carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-04.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-10
Trial Details
NCT Number NCT05987358
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Biliary Carcinoma
Enrollment 165 participants
Start Date 2023-09-21
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-11